Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/4/2019
SIETES contiene 92717 citas

 
 
 1 a 20 de 3687 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Anónimo. Towards better patient care: drugs to avoid in 2019. Prescrire Int 2019;39:abril. [Ref.ID 103075]
2.Enlace a cita original Cita con resumen
Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, Peters C, Zhyzhneuskaya S, Al-Mrabeh A, Hollingsworth KG, Rodrigues A, Rehackova L, Adamson AJ, Sniehotta FF, Mathers JC, Ross HM, McIlvenna Y, Welsh P, Kean S, Ford I, McConnachie A, Messow C-M, Sattar N, Taylor R. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. The Lancet Diabetes & Endocrinology 2019:6 de marzo. [Ref.ID 103052]
3. Cita con resumen
4.Enlace a cita originalTiene citas relacionadas Cita con resumen
Newman CB, Preiss D, Tobert JA, Jacobson TA, Page II RL, Goldstein LB, Chin C, Tannock LR, Miller M, Raghuveer G, Duell PB, Brinton EA, Pollak A, Braun LT, Welty FK. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology 2019;39:enero. [Ref.ID 103011]
5.Enlace a cita original Cita con resumen
Abrahami D, Douros A, Yin H, Hu OHY, Faillie J-L, Montastruc F, Platt RW, Bouganim N, Azoulay L. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. BMJ 2018;363:5 de diciembre. [Ref.ID 102894]
6. Cita con resumen
Young K. Diabetes guidelines updated. Journal Watch 2018:1. [Ref.ID 102893]
8.Enlace a cita original Cita con resumen
Richman IB, Ross JS. Weighing the harms and benefits of using statins for primary prevention: raising the risk threshold. Ann Intern Med 2018:4 de diciembre. [Ref.ID 102877]
9.Enlace a cita original Cita con resumen
Ueda P, Svanström H, Melbye M, Eliasson B, Svensson A-M, Franzén S, Gudbjörnsdottir S, Hveem K, Jonasson C, Pasternak B. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ 2018;363:14 de noviembre. [Ref.ID 102869]
10.Enlace a cita original Cita con resumen
Akturk HK, Taylor DD, Camsari UM, Rewers A, Kinney GL, Shah VN. Association between cannabis use and risk for diabetic ketoacidosis in adults with type 1 diabetes. JAMA Intern Med 2018:5 de noviembre. [Ref.ID 102851]
11.Enlace a cita original Cita con resumen
Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2018:9 de noviembre. [Ref.ID 102850]
12.Enlace a cita originalTiene citas relacionadas Cita con resumen
The ASCEND Study Collaborative Group. Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med 2018;379:18 de octubre. [Ref.ID 102845]
13.Enlace a cita originalTiene citas relacionadas Cita con resumen
The ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med 2018;379:18 de octubre. [Ref.ID 102844]
14.Enlace a cita original Cita con resumen
Nguyen TTH, Roussin A, Rousseau A, Montastruc J-L, Montastruc F. Role of serotonin transporter in antidepressant-induced diabetes mellitus: A pharmacoepidemiological–pharmacodynamic study in VigiBase®. Drug Saf 2018;41:noviembre. [Ref.ID 102840]
15.Enlace a cita originalTiene citas relacionadas Cita con resumen
Samper E. Así influyen las farmacéuticas sobre los médicos . eldiario.es 2018:18 de octubre. [Ref.ID 102834]
16. Cita con resumen
Anónimo. FDA warns SGLT2 inhibitors can cause flesh-eating genitali infection. DIA Daily 2018:1. [Ref.ID 102830]
17.Enlace a cita original Cita con resumen
Chang HY, Singh S, Mansour O, Baksh S, Alexander GC. Association between sodium-glucose cotransporter 2 inhibitors and lower extremity amputation among patients with type 2 diabetes. JAMA Intern Med 2018:13 de agosto. [Ref.ID 102824]
18.Enlace a cita original Cita con resumen
Douros A, Dell'Aniello S, Yu OHY, Filion KB, Azoulay L, Suissa S. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study. BMJ 2018;362:k2693. [Ref.ID 102821]
19.Enlace a cita original Cita con resumen
Sinha MS, Curfman GD, Carrier MA. Antitrust, market exclusivity, and transparency in the pharmaceutical industry. JAMA 2018;319:12 de junio. [Ref.ID 102779]
20.Enlace a cita originalTiene citas relacionadas Cita con resumen
Sénat M-V, Affres H, Letourneau A, Coustols-Valat M, Cazaubiel M, Legardeur H, Jacquier JF, Bourcigaux N, Simon E, Rod A, Héron I, Castera V, Sentilhes L, Bretelle F, Rolland C, Morin M, Deruelle P, De Carne C, Maillot F, Beucher G, Verspyck E, Desbriere R, Laboureau S, Mitanchez D, Bouyer J, for the Groupe de Recherche en Obstétrique et Gynécologie (GROG). Effect of glyburide vs subcutaneous insulin on perinatal complications among women with gestational diabetes. A randomized clinical trial. JAMA 2018;319:1 de junio. [Ref.ID 102766]
Seleccionar todas
 
 1 a 20 de 3687 siguiente >>